Janssen/Legend’s Cilta-Cel Responses Could Make Up For Second-To-Market Position

Mitigation Strategy Lessens Neurotoxicity Of CAR-T In Myeloma

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.